Literature DB >> 19124115

Increased cyclooxygenase-2 expression in juvenile polyposis syndrome.

W Arnout van Hattem1, Lodewijk A A Brosens, Susan Y Marks, Anya N A Milne, Susanne van Eeden, Christine A Iacobuzio-Donahue, Ari Ristimäki, Francis M Giardiello, G Johan A Offerhaus.   

Abstract

BACKGROUND & AIMS: Gastrointestinal juvenile polyps may occur in juvenile polyposis syndrome (JPS) or sporadically. JPS is an autosomal-dominant condition caused by a germline defect in SMAD4 or BMPR1A in 50% to 60% of cases, and is characterized by multiple juvenile polyps, predominantly in the colorectum. JPS has an increased risk of gastrointestinal malignancy but sporadic juvenile polyps do not. Cyclooxygenase-2 (COX-2) expression is increased in gastrointestinal tumorigenesis and familial adenomatous polyposis. Inhibition of COX-2 leads to regression of colorectal adenomas in familial adenomatous polyposis patients and inhibits gastrointestinal tumorigenesis. To investigate the role of COX-2 in juvenile polyps, we compared the expression of COX-2 in juvenile polyps from a well-defined group of juvenile polyposis patients and sporadic juvenile polyps.
METHODS: COX-2 expression was assessed in 24 genetically well-defined JPS patients and 26 patients with sporadic juvenile polyps using tissue microarray analysis. Two additional markers, Hu-antigen R, a stabilizer of messenger RNA, and CCAAT/enhancer-binding protein beta, a transcription factor, both associated with increased COX-2 expression, also were investigated.
RESULTS: Increased COX-2 expression in JPS patients was noted compared with patients with sporadic juvenile polyps (P < .001). Also, JPS patients with a BMPR1A germline defect had higher COX-2 expression than did JPS patients in whom no germline mutation was detected. High COX-2 levels correlated with increased cytoplasmic Hu-antigen R expression in JPS polyps (P = .022), but not in sporadic juvenile polyps.
CONCLUSIONS: Juvenile polyposis and sporadic juvenile polyps show distinctive expression profiles of COX-2 that may have clinical implications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19124115      PMCID: PMC2698594          DOI: 10.1016/j.cgh.2008.07.030

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  41 in total

1.  The RNA-binding protein HuR regulates the expression of cyclooxygenase-2.

Authors:  Sibani Sengupta; Byeong-Churl Jang; Ming-Tao Wu; Ji-Hye Paik; Henry Furneaux; Timothy Hla
Journal:  J Biol Chem       Date:  2003-04-18       Impact factor: 5.157

2.  Human cyclooxygenase-2 cDNA.

Authors:  T Hla; K Neilson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

3.  Role of the RNA-binding protein HuR in colon carcinogenesis.

Authors:  Isabel López de Silanes; Jinshui Fan; Xiaoling Yang; Alan B Zonderman; Olga Potapova; Ellen S Pizer; Myriam Gorospe
Journal:  Oncogene       Date:  2003-10-16       Impact factor: 9.867

4.  Solitary juvenile polyps: not a marker for subsequent malignancy.

Authors:  K P Nugent; I C Talbot; S V Hodgson; R K Phillips
Journal:  Gastroenterology       Date:  1993-09       Impact factor: 22.682

5.  Colorectal neoplasia in juvenile polyposis or juvenile polyps.

Authors:  F M Giardiello; S R Hamilton; S E Kern; G J Offerhaus; P A Green; P Celano; A J Krush; S V Booker
Journal:  Arch Dis Child       Date:  1991-08       Impact factor: 3.791

6.  BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling.

Authors:  Xi C He; Jiwang Zhang; Wei-Gang Tong; Ossama Tawfik; Jason Ross; David H Scoville; Qiang Tian; Xin Zeng; Xi He; Leanne M Wiedemann; Yuji Mishina; Linheng Li
Journal:  Nat Genet       Date:  2004-09-19       Impact factor: 38.330

7.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

Authors:  F M Giardiello; S R Hamilton; A J Krush; S Piantadosi; L M Hylind; P Celano; S V Booker; C R Robinson; G J Offerhaus
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

Review 8.  CCAAT-enhancer binding protein: a component of a differentiation switch.

Authors:  R M Umek; A D Friedman; S L McKnight
Journal:  Science       Date:  1991-01-18       Impact factor: 47.728

9.  De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine.

Authors:  Anna-Pavlina G Haramis; Harry Begthel; Maaike van den Born; Johan van Es; Suzanne Jonkheer; G Johan A Offerhaus; Hans Clevers
Journal:  Science       Date:  2004-03-12       Impact factor: 47.728

10.  Juvenile polyposis--a precancerous condition.

Authors:  J R Jass; C B Williams; H J Bussey; B C Morson
Journal:  Histopathology       Date:  1988-12       Impact factor: 5.087

View more
  4 in total

1.  Damnacanthal, a noni component, exhibits antitumorigenic activity in human colorectal cancer cells.

Authors:  Thararat Nualsanit; Pleumchitt Rojanapanthu; Wandee Gritsanapan; Seong-Ho Lee; Darunee Lawson; Seung Joon Baek
Journal:  J Nutr Biochem       Date:  2011-08-17       Impact factor: 6.048

Review 2.  Juvenile polyposis syndrome.

Authors:  Lodewijk Aa Brosens; Danielle Langeveld; W Arnout van Hattem; Francis M Giardiello; G Johan A Offerhaus
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

Review 3.  Familial colon cancer syndromes: an update of a rapidly evolving field.

Authors:  Swati G Patel; Dennis J Ahnen
Journal:  Curr Gastroenterol Rep       Date:  2012-10

4.  Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG).

Authors:  Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill
Journal:  Gut       Date:  2019-11-28       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.